



Stabilis



Dihydralazine mesilate



Noms commerciaux

| | |
|-----------|------------------|
| Nepresol | Allemagne, Grèce |
| Nepressol | France, Maroc |



Facteur influençant la stabilité

| | | | | |
|--|--|--|--|------|
| | | | | 3613 |
|--|--|--|--|------|



Compatibilités

| | Dihydralazine mesilate : 0.5 & 1.5 mg/ml Clonidine hydrochloride : 0.009 & 0.03 mg/ml | | 4130 |
|--|--|--|------|
| | Dihydralazine mesilate : 0,05 mg/ml Insulin aspart : 1 UI/ml | | 1508 |
| | Dihydralazine mesilate : 0,25 >>0,75 mg/ml Metamizol sodium : 25 >>50 mg/ml | | 4490 |
| | Dihydralazine mesilate | | 3613 |



Voie d'administration

























Bibliographie

| | Type | Source |
|------|-------------|--|
| 1508 | Revue | Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124. |
| 3613 | Laboratoire | Dihydralazine (Nepressol®) - Résumé des caractéristiques du produit Primius Lab 2013 |
| 4130 | Revue | Koller AK, Krebs S, Dörje F. Untersuchungen zur Kompatibilität von Clonidin mit häufig eingesetzten Arzneimittel auf Intensivstationen. Pharmaceutics 2021 , 13, 21. |
| 4490 | Revue | Koller A.K, Fischer O, Krebs S. Medication Safety in Intravenous Therapy: A Compatibility Study and Analysis of Reaction Products of Dihydralazine and Metamizole. Sci Pharm 2020 ; 88, 25 |



Dictionnaire

| | |
|---|--|
|  Vasodilatateur |  Injectable |
|  Noms commerciaux |  Facteur influençant la stabilité |
|  Solvant |  Glucose 5% |
|  Provoque |  Dégradation |
|  Compatibilités |  Molécule |
|  Bibliographie |  Compatible |
|  NaCl 0,9% ou glucose 5% |  Instabilité chimique |
|  Incompatible |  Chlorure de sodium 0,9% |
|  Voie d'administration |  Intraveineuse |
|  Perfusion intraveineuse |  Perfusion continue |
|  Bibliographie |  Dictionnaire |